
Interstate health care compact bills in limbo as 60-day session enters homestretch
Mar. 17—SANTA FE — Amid a chronic health care worker shortage, New Mexico lawmakers are weighing proposals to make it easier for licensed out-of-state practitioners to work in the state.
A package of bills would, if passed, allow New Mexico to join various interstate medical licensing compacts and streamline the licensing process for physicians.
New Mexico is a member of a 40-state nursing compact, but has not joined similar compacts for doctors, physical therapists, dentists, mental health counselors and audiologists.
With just five days left in the 60-day legislative session, some medical compact bills have already passed one chamber, but none have as of yet crossed the finish line.
Though similar piecemeal bills have stalled in past years, this is the first time advocates are pushing for a comprehensive package to make it through the Legislature.
One of the compact bills, House Bill 243, aimed at allowing physicians to apply for an expedited license in member states, was discussed in the Senate Judiciary Committee on Monday but not voted on.
Sen. Joseph Cervantes, D-Las Cruces, the committee's chairman, expressed concern about New Mexico physicians being subject to subpoenas issued in another state.
He also referred to as interstate compacts as business ventures, adding, "It looks like a pretty creative way to make a buck."
But Cervantes also said he's willing to work with advocates to try to address concerns.
"We want to have more doctors in New Mexico and we want to work with you to make that happen," Cervantes said during Monday's meeting.
Rep. Marian Matthews, D-Albuquerque, the bill's sponsor, said the hearing broke the ice for the bill and hinted at possible compromise amendments to come.
"The committee's identified what's important ... and now we're going to go take a moment and look at it and see if there's a way to move forward," she told the Journal.
Another member of the committee, Sen. Katy Duhigg, D-Albuquerque, said in a Monday interview the compact bills often feature problematic language that advocates don't want to change.
Duhigg, an attorney, said a proposed social work compact bill came in cleaner than other compact legislation and the amended version that passed through the Senate Judiciary Committee cleaned it up even more.
"That is the example of how they should do it. They were reasonable in removing language that was not right for New Mexico, and we passed the compact," she said.
She also said it could be very dangerous to let a private commission make laws about what New Mexico does in medical care, pointing to issues like reproductive health care or gender-affirming health care. Dozens of other states joining compacts doesn't unequivocally mean New Mexico should, she said.
"If other states think it's cool to let some private organization make their laws for them, OK, but that is no reason for us to do so," Duhigg said.
A way to stanch chronic worker shortage?
The interstate compacts are aimed at alleviating a longstanding health care provider shortage, especially in rural New Mexico.
Despite recent efforts to boost funding for health care training programs at New Mexico colleges and universities, the state had an average shortage of 5,000 health care workers between 2018 and 2013, according to legislative data.
Most of New Mexico's neighboring states are already members of five or more of the interstate compacts, according to Think New Mexico, a Santa Fe-based think tank that has advocated for the legislation.
Founder and Executive Director Fred Nathan described the health care compacts as the most impactful short-term fix to New Mexico's doctor shortage crisis.
"These are bills that the overwhelming number of states have already approved, and we have a dire shortage of health care workers. So it makes sense that these bills should all be passed this session," Nathan said.
In a legislative analysis, the state Department of Health concluded that passage of the medical licensure compact would reduce the administrative burden and the time required to become licensed in New Mexico, which could increase available physicians.
The DOH analysis also said an increase in primary care providers could reduce the number of emergency department visits in New Mexico by making it easier for patients to access routine care.
But while legislation may be advancing through the legislative process, some advocates aren't entirely happy with changes made along the way.
Matt Shafer, deputy policy director of the National Center for Interstate Compacts, emailed Cervantes on Monday with concerns that the committee changes to Senate Bill 105, concerning social work licensure compacts, would "prohibit New Mexico from being seated on the compact commission," according to an email shared with the Journal.
Kristina Fisher, associate director of Think New Mexico, explained that the national commission can bar states from joining the compacts under the reasoning that, "you can pass what you want, but we can't accept it unless it's substantively the same as what every other state agreed to."
She said if the Legislature passes the compact bills, the national commission could vote to add New Mexico to the compacts before the end of the year.
Nathan said trial lawyers are often against the compacts because they don't want to expand immunity in lawsuits — language in some of the bills states that officers and employees of the interstate commission are immune from suit and liability. Nathan described trial lawyers' interests as self-serving, not wanting to grant lawsuit immunity, "even if the probability of suing these people is beyond remote."
But Duhigg later denied that, saying, "This is not a trial lawyer thing" and some advocates aren't willing to compromise to fix bad language.
Nathan said the need for interstate compacts pairs with a need to reform the state's medical malpractice statutes. A bill to limit attorney fees in medical malpractice cases died in its first committee last week.
"The issue is not going away, and we're not going away," Nathan said.
Fisher added, "And unfortunately, the doctors are going away — and that's what we need to address."
Hospital mergers also on lawmakers' minds
The House voted Monday to approve a bill, House Bill 586, giving the secretary of the state Health Care Authority the ability to decide whether to approve proposed mergers and acquisitions of hospitals and other health care facilities.
"The focus of this is hospitals, and making sure the quality of care and the way we treat our workforce is the same — or better — after this transaction," said House Majority Leader Reena Szczepanski, D-Santa Fe, during Monday's debate
New Mexico has the nation's highest percentage of hospitals owned by private equity firms, as 17 of the state's 45 private hospitals are owned by such firms, according to a legislative analysis.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout
New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology New York, May 30, 2025 (GLOBE NEWSWIRE) -- PESG Research is releasing a report today examining PolyPid Ltd.*, an innovative late-stage biopharmaceutical company developing revolutionary localized drug delivery technologies for surgical infection prevention. The below report explores the company's breakthrough PLEX platform technology, its upcoming topline phase 3 data, and potential implications for transforming surgical care practices in the multi-billion dollar surgical site infection prevention market. This report contains sponsored content, please see refer to the disclaimers and disclosures included at the end of this report. Executive Summary The surgical site infection (SSI) prevention landscape stands at a potential inflection point as PolyPid Ltd. prepares to announce topline results from its pivotal SHIELD II Phase 3 trial by the end of Q2 2025. The company's D-PLEX100 represents a paradigm shift in infection prevention, utilizing novel polymer-lipid encapsulation matrix (PLEX) technology to deliver sustained antibiotic release directly at surgical sites for 30 days. With SSIs affecting up to 30% of colorectal surgeries and imposing substantial healthcare costs estimated at $10 billion annually in the US and EU, successful development of D-PLEX100 could address a critical unmet medical need. The FDA's assignment of Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product (QIDP) designations underscores the regulatory recognition of this approach's potential Critical Challenge of Surgical Site Infections Surgical site infections remain one of healthcare's most persistent challenges, representing 20% of all healthcare-associated infections in US hospitals. Despite advances in surgical techniques and prophylactic protocols, SSI rates in high-risk procedures like colorectal surgery can reach 30%, leading to extended hospital stays of 7-11 additional days and mortality risk increases of 2-11 fold. The economic burden is staggering, with direct costs averaging $11,000-26,000 per infection and total annual costs reaching approximately $10 billion in the US alone. Current prevention strategies rely primarily on systemic antibiotic prophylaxis administered intravenously 30-60 minutes before surgery. However, this approach faces fundamental limitations. Surgical incisions disrupt local blood flow, significantly limiting antibiotic penetration to the precise site where infections occur. Moreover, systemic administration exposes patients to higher drug concentrations throughout the body, potentially increasing toxicity risks and contributing to antimicrobial resistance development. PLEX Technology: A Novel Approach to Localized Drug Delivery PolyPid's proprietary PLEX technology represents a sophisticated advancement in controlled drug delivery systems. The platform creates thousands of alternating layers of biocompatible polymers and lipids that physically embed active pharmaceutical ingredients. As these outer layers gradually disintegrate upon exposure to body fluids, they enable precise, predetermined drug release rates spanning several days to months. For D-PLEX100, this technology pairs with doxycycline, a broad-spectrum antibiotic effective against both gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant strains. The formulation achieves local antibiotic concentrations 10-115 times higher than systemic administration while using only a fraction of the total drug amount, potentially minimizing systemic exposure and associated side effects. Clinical Development Progress and Regulatory Recognition The clinical development program for D-PLEX100 has demonstrated encouraging signals across multiple surgical contexts. In Phase 2 abdominal surgery trials, D-PLEX100 plus standard of care achieved a statistically significant 59% reduction in the primary endpoint compared to standard of care alone (p=0.0086). Perhaps more notably, the treatment group experienced zero deaths compared to five in the control arm within 60 days post-surgery. The pivotal SHIELD I Phase 3 trial, while not meeting its primary endpoint in the full intent-to-treat population, revealed compelling efficacy in a pre-specified subgroup analysis. Among patients with large surgical incisions (>20 cm), D-PLEX100 demonstrated a statistically significant 54% reduction in the composite primary endpoint of SSIs, reinterventions, and mortality (p=0.0032). This finding directly informed the design of the ongoing SHIELD II trial, which focuses specifically on this higher-risk patient FDA's regulatory designations reflect recognition of D-PLEX100's potential significance. Breakthrough Therapy designation is reserved for drugs that demonstrate substantial improvement over existing treatments for serious conditions. Fast Track designation facilitates more frequent FDA communications and potentially accelerated review timelines. The QIDP designation provides additional market exclusivity incentives for addressing antimicrobial resistance challenges. SHIELD II: A Potentially Definitive Study The ongoing SHIELD II Phase 3 trial represents a carefully designed study incorporating lessons learned from SHIELD I. Following an independent Data Safety Monitoring Board's review of unblinded efficacy data from the first 430 enrolled patients, the board recommended concluding the study at 800 patients—the lowest sample size reassessment option available. This recommendation, while requiring additional enrollment beyond the initially planned 624 patients, may suggest positive efficacy trends in the analyzed interim data. The study's multinational design spans approximately 60 centers across the United States, Europe, and Israel, enhancing the generalizability of results across different healthcare settings and patient populations. The primary endpoint focuses on a composite of SSI events, reinterventions, and mortality within 30 days post-surgery, as adjudicated by an independent committee. Broader Industry ImplicationsSuccess of D-PLEX100 could catalyze broader adoption of localized drug delivery approaches in surgical settings. The technology's platform nature suggests potential applications beyond infection prevention, including localized chemotherapy delivery through the company's OncoPLEX program, currently in preclinical development for solid tumor treatment. The substantial market opportunity—with approximately 12 million eligible procedures annually in the US and 8 million in Europe—underscores the potential healthcare impact. PolyPid has already secured European commercialization rights through a partnership with Advanz Pharma, valued at up to $115 million plus royalties, while advancing discussions for US market partnerships. Conclusion As the pharmaceutical industry grapples with antimicrobial resistance and healthcare systems seek cost-effective solutions to persistent clinical challenges, D-PLEX100's approaching data readout represents a potentially significant milestone. The convergence of compelling preclinical and early clinical data, regulatory recognition, and substantial unmet medical need positions this development as one to monitor closely in the evolving landscape of surgical infection News Highlight from PolyPid: PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections >> Click here to Subscribe for more updates like this or go to * Legal Disclaimer & Disclosure: Nothing in this report constitutes medical, financial or any form professional or licensedadvice. This report is published by 'PESG Research', a digital promotional content brand who's operators are compensated to provide digestable and favorabel coverage of companies. This report contains and is a form of paid promotional content or advertising for PolyPid Ltd and was produced as part of the fee's they pay PESG's operators, Arx Advisory Ltd. This report has not been reviewed or approved by PolyPId prior to publication and it does not represent an official communication from PolyPid. The operators of PESG Research received or are expected to receive a monthly recurring fee of five thousand united states dollars via wire transfer from PolyPid as part of an ongoing agreement starting May 1, 2025 in return for distribution and promotional coverage services, and receive additional monthly compensation for non promotional unrelated data and advisory services on top of that. Please review the full disclaimers and compensation disclosures here for further details: Readers are advised to refer to the official materials of the company aforementioned. The report should not be treated as objective.
Yahoo
3 hours ago
- Yahoo
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
Company Is Advancing Use of Novel Doxorubicin-containing Microneedle Array (D-MNA) Patch in Veterinary Oncology as an Orphan Drug Philadelphia, Pennsylvania--(Newsfile Corp. - June 9, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development plan to treat external squamous cell carcinoma (SCC) under Investigational New Animal Drug (INAD File No.013880). The Company, in December 2024, received a Minor Use in Major Species Designation (MUMS) for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. The product development plan is designed to seek concurrence of the FDA under MUMS designation. MUMS is a status similar to Orphan Drug status for human drugs. It entitles the Company to an extended 7-year period of exclusive marketing following approval or conditional approval, provided that the Company meets all requirements for maintaining the designation. Doxorubicin-containing microneedle array (D-MNA) is a patent protected dissovable transdermal patch with cellulose based microneedle arrays that are tip-loaded with doxorubicin. After application, the microneedles function by penetrating the strateum corneum layer of the skin, create a temporary microchannel, penetrate the tumor, dissolve and release doxorubicin into the target tumor, and eradicate the cancer cells. "In Veterinary Medicine, where there are only a handful of approved oncology drugs, we believe developing a non-invasive treatment for equine SCC represents an untapped and unmet market opportunity potentially in the range of $250 million," stated Dr. Raza Bokhari, Executive Chairman & CEO. "The submission to the FDA of a novel product development program may provide us a first mover advantage and sets the stage to consider other companion animal species and types of cancer." Squamous Cell Carcinoma (SCC) in Horses SCC is a mucocutaneous skin tumor in horses, primarily affecting adult or aged horses with white or partially white coats. Breeds like Appaloosa, Belgian, American Paint, and Pinto are particularly susceptible. SCC often develops in areas with minimal pigmentation and sparse hair, notably around mucous membranes. More specifically, tumors are mainly seen around the eyes, lips, nose, anus, and external genitalia. The overall incidence of SCC is 2-3% and recent estimates of the US horse population range from 6.6 to 7.25 million horses. Current treatment includes surgery to remove the largest mass, cryotherapy of the smaller mass, and local injection of a chemotherapy drug. In some cases, a topical chemotherapeutic drug will be prescribed in the form of drops (tumors near the eye) or cream (tumors in other parts of body). Additionally, some horses are put on an oral drug called piroxicam that may slow the return of the cancerous cells. Product Development Plan The clinical study, SKNJCT-004, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 50 horses presenting with external SCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The horses will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA. The horses will be assessed for outcomes over six (6) months from index dose. The primary effectiveness variable will be a veterinarian's assessment for complete clinical response of the target tumor at day 90 according to RECIST. The high-dose, 200μg D-MNA, proposed in the study is the maximum dose that was used in the Company's Phase 1 safety and tolerability human study (SKNJCT-001) completed in March 2021. SKNJCT-001 met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-limiting toxicities (DLTs), or serious adverse events (SAEs). Furthermore, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examinations. The study also describes the efficacy of the investigational product, D-MNA, with 6 participants experiencing complete responses. The complete response is defined as the disappearance of BCC histologically in the final excision at the end of study visit. The participants profile demonstrating complete responses was diverse, and all participants (6/6) had nodular subtype of BCC. The Company also has SKNJCT-003 Phase 2 clinical study currently underway in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025 the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to Ninety (90) subjects. The Company also announced expanding clinical trial sites in Europe. The Company also has a clinical design (SKNJCT-004) currently underway in United Arab Emirates (UAE). The study is expected to randomize 36 patients in four sites in UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company. In April 2025, the Company announced entering into a binding letter of intent to acquire Antev Ltd. ("Antev"), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. For further information contact: Carolyn Bonner, President(610) 636-0184cbonner@ Anna Baran-Djokovic, SVP Investor Relations(305) 615-9162adjokovic@ About Medicus Pharma Ltd: Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in UAE. In April 2025, the Company also announced entering into a binding letter of intent to acquire Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. The transaction with Antev is subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all. Cautionary Notice on Forward-Looking Statements Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding its comprehensive product development plan to treat external SCC for horses, the commencement of its development plan, the market opportunity a non-invasive treatment for equine SCC and the Company's opportunity to develop, gain approval for and commercialize its product to meet such opportunity, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study, the potential Antev transaction, including the entry into a definitive agreement in respect of the Antev transaction, the closing of the transaction or the timing thereof, the potential benefits of the Antev transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto, the results of the interim analysis, which may or may not correlate with the findings of the clinical study report that will be compiled following completion of the phase 2 study, the Company's plans and expectations concerning, and future outcomes relating to, the submission and advancement of the phase 2 clinical protocol, the randomization of patients and size of the study, the Company's intention to complete and submit an interim data analysis to the FDA and to request a Type C meeting and the timing thereof, the Company's aim to fast fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on EDGAR and on SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Company's long form prospectus accessible on the Company's profile on EDGAR at and on SEDAR+ at . Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. To view the source version of this press release, please visit
Yahoo
4 hours ago
- Yahoo
Hundreds of bills failed at the Capitol this session. See what could have been law.
The Connecticut Legislature passed numerous bills this session on hot button issues including immigration, child care and special education. But hundreds more proposals failed to make it to the finish line, covering an array of issues from restrictions on private equity to regulating homeschooling to the regulation of artificial intelligence. And even within those bills that passed, oftentimes measures included in the original drafts were removed to ensure bipartisan support. Connecticut lawmakers proposed several bills to restrict private equity's role in Connecticut hospitals after Prospect Medical Holdings filed for Chapter 11 bankruptcy this past year raising questions about patient care. But no bill made it to a vote in either the House or Senate. Prospect, which operates Manchester Memorial, Rockville General and Waterbury Hospital, has faced fiscal challenges in many of its hospitals in the state, from delayed payments to physicians and vendors to a shortage of health care providers. Sen. Saud Anwar, Senate chairman of the Public Health Committee, argued for the restriction of private equity, calling it the responsible thing to do 'under the current circumstances where we have three hospitals that have been bankrupted by private equity and also the infrastructure of radiology services in the state of Connecticut has been harmed by private equity.' 'So much more harm to our patients has happened through private equity takeover of health care entities,' the senator has said. SB 1507 would have prohibited private equity companies and real estate investment trusts from acquiring or increasing direct or indirect ownership interest in or operational or financial control over a hospital or health system, according to the bill's analysis. HB 6873, Gov. Ned Lamont's bill, focused on the strengthening of the review of health care entity transactions, expanding the transactions that require prior notice to the attorney general, according to the bill's analysis. House Speaker Matt Ritter, D-Hartford, said during a press conference with days before the session's end that time was running out. The governor noted Thursday that he was surprised that the legislation did not pass. 'Everybody in this building was hostile to private equity until last night,' he said. But Anwar said 'it's my understanding Gov. Lamont played a role in private equity bills not moving forward.' Rob Blanchard, the governor's communication's director said that 'despite the governor's best efforts to work collaboratively with the public health committee on private equity, the co-chairs chose to not bring out a single bill on this issue and took no action. 'Only the legislature can bring out legislation and move it forward,' he said. 'Any inaction on this issue lies with them.' While state senators voted overwhelmingly for a bill seeking oversight of artificial intelligence, it did not pass the House. Lamont also remained adamant against slowing down one of the world's developing industries. In a compromise designed to attract Republican votes, the bill was watered down by removing two sections covering 188 lines that would have allowed lawsuits against AI developers if 'the use of a high-risk artificial intelligence system resulted in algorithmic discrimination against one or more consumers.' The Senate bill included the creation of an AI task force, the formation of a Connecticut technology advisory board, among others. The measure would have also established 'various requirements concerning artificial intelligence systems and required the Department of Economic and Community Development to establish an artificial intelligence regulatory sandbox program,' according to a nonpartisan bill analysis. 'Connecticut had a real opportunity this session to lead on this issue,' said Sen. James Maroney, D-Milford, chair of the General Law Committee who led the state's efforts to regulate artificial intelligence. 'We passed a strong framework in the Senate, but for a second year in a row, we were unable to get the bill across the finish line.' No legislation to regulate homeschooling was introduced this session despite urgency from child advocates. Homeschooling parents and advocates gathered at the state Capitol this week where they celebrated their successful advocacy against state regulations for homeschooling. The debate of the regulation of homeschooling was brought to the forefront after the Office of the Child Advocate released a report in early May that found that withdrawals of children from public schools for homeschooling had been used to hide abuse. The legislature's Education Committee and the Committee on Children held a joint hearing last month to discuss the state's homeschooling policies, with both the Office of the Child Advocate and the Connecticut Association of Public School Superintendents calling for increased oversight of homeschooling. The discussion came on the heels of a disturbing case where a 32-year-old man was allegedly held captive and abused by his stepmother in a Waterbury residence for 20 years. The alleged victim told investigators he was withdrawn from school at 11 years of age after being told to lie to DCF and say everything was fine, according to the warrant affidavit. At a press conference Wednesday morning, Ritter said he thought homeschooling would likely come up again during next year's legislative session. SB 1371, a bill that would have ended arbitrary and politically motivated teacher terminations did not make it to a vote in the House. The legislation passed the Senate. Connecticut Education Association President Kate Dias said in a statement that House leadership 'turned their backs on the 54,000 public school educators in our state and on the broader labor movement at a time when workers are under attack and protections are needed more than ever.' The bill required a 'showing of just cause when a nontenured or tenured public school teacher is terminated for the reasons allowed by existing law such as inefficiency, incompetence, insubordination, moral misconduct, disability, elimination of a position to another teacher, or other due and sufficient reasons,' according to the bill's nonpartisan analysis.' The current law allows for termination for one of the above reasons without any specified showing, the bill's analysis further states. Legislation that would ban female genital mutilation of minors did not make it to the floor of either chamber for a vote. SB 1438 would have established the crime of mutilation of female genitalia of minors as a Class D felony. Similar efforts to ban the practice have failed in previous years. Zehra Patwa, co-founder of the anti FGM/C movement WeSpeakOut, a survivor of FGM/C, wrote in her testimony in support of the bill that according to the Centers for Disease Control and Prevention, 'half a million women and girls living in the United States have been cut or at risk of FGM/C.' 'Over 2,500 such women and girls live in Connecticut, but this is often regarded as a severe underestimate as it is difficult to effectively quantify the risk,' she wrote. Connecticut lawmakers considered a bill that would consolidate and strengthen the state's existing hate crime statutes into a new chapter of state laws, making it easier for law enforcement to charge and prosecute criminals with those particular crimes, according to Lamont's office. The bill unanimously passed the House but did not make it out of the Senate. HB 6872, the governor's proposed law, originated from the Connecticut Hate Crimes Advisory Council. The bill modified the intent standard, removing the element that a defendant must have acted 'maliciously.' Opponents of the bill cited concerns about what they referred to as vague language in the bill, which they feared would be used to suppress free speech and others cited lack of clarity in several sections of the bill. But advocates for the bill, including the executive assistant states attorney for the Division of Criminal Justice and the commissioner of the Department of Emergency Services and Public Protection, argued that it would make the state a safer place and increase sentences for hate-motivated felonies and misdemeanors. While a bill that would add Connecticut to the short list of states providing jobless benefits to strikers won final passage last week in the legislature, Gov. Ned Lamont has said he will veto it. 'I haven't supported that,' the governor said in a press conference Friday. 'I never have. Nothing compromises your job security more than a bill like striking workers. When it comes to job security, growing jobs in this state, I think it is a vote that is important for me to veto.' SB 8 generally 'limits how employers at certain warehouses may use quotas for their employees and makes striking workers (in any type of employment) eligible for unemployment benefits after they have been on strike for 14 consecutive days,' according to the nonpartisan bill analysis. The CT Mirror contributed to this report. Reporting from Courant reporter Christopher Keating is contained in this article.